Best Growth Stocks to Buy for October 5th

Zacks highlighted three #1-ranked stocks: Petco (WOOF), Five Below (FIVE) and Oscar Health (OSCR). Their current-year earnings consensus estimates rose 26.3%, 15.2% and 63.4%, respectively, over the past 60 days; each also has a PEG ratio below its cited industry comparison. The article is stock-pick commentary and reports no realized earnings results or market reaction.

Analysis

This is a screening piece, not a differentiated catalyst: estimate revisions can signal improving expectations, but the article supplies no operating evidence to test whether revisions are durable. The PEG comparisons are especially weak as a standalone valuation signal when earnings are volatile or unusually sensitive to one-year assumptions.

For WOOF, the key question is whether any earnings improvement reflects sustained traffic, basket growth and better unit economics—not simply cost actions. Chewy, Amazon and mass retailers constrain pricing power; a miss in comparable sales or margin progress would undermine the revision signal. For FIVE, value-seeking demand may support traffic, but discretionary low-ticket goods remain exposed to consumer trade-down, inventory execution and competition from dollar stores and online marketplaces. Monitor comparable sales, gross margin and inventory rather than the rank.

OSCR has the largest estimate-revision signal but also the most policy and underwriting sensitivity. Enrollment growth is not sufficient evidence of attractive economics: medical-cost trends, risk adjustment and ACA rate-setting can change profitability, while regulatory changes could alter the addressable opportunity over a 6–18 month horizon. The article offers no data on those drivers. The separate D-Wave promotional claim is unrelated to these three screens and provides no basis for a QBTS trade.

Near term, these signals may attract momentum flows; over 1–3 months, earnings updates and enrollment/medical-cost disclosures should determine whether revisions convert to cash earnings. No outright position is justified from this article alone.

Key Decisions for Investors

• Keep WOOF and FIVE on an event-driven watchlist, not as automatic buys. Reassess after the next reported comparable-sales, gross-margin and inventory update; abandon the positive thesis if sales weaken while margins or inventory deteriorate.
• Treat OSCR as a higher-risk catalyst watch. Before considering exposure, verify medical-cost trends, risk-adjustment effects, enrollment quality and current ACA rate/regulatory developments; a favorable earnings estimate alone is not enough.
• Do not infer a trade in QBTS from the unrelated SaaS promotion. The article provides no new company-specific evidence for D-Wave.
• Falsification across the screen: subsequent guidance or reported results fail to support the upward estimate revisions. Without current valuation, price action and operating data, avoid sizing a directional trade.